247 related articles for article (PubMed ID: 26659615)
21. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Rollason V; Laverrière A; MacDonald LC; Walsh T; Tramèr MR; Vogt-Ferrier NB
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008455. PubMed ID: 26919630
[TBL] [Abstract][Full Text] [Related]
22. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III.
Bodem JP; Schaal C; Kargus S; Saure D; Mertens C; Engel M; Hoffmann J; Freudlsperger C
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Apr; 121(4):367-72. PubMed ID: 26795450
[TBL] [Abstract][Full Text] [Related]
23. Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin.
Gönen ZB; Yılmaz Asan C
Cranio; 2017 Sep; 35(5):332-336. PubMed ID: 27363584
[TBL] [Abstract][Full Text] [Related]
24. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
25. Medication-related osteonecrosis of the jaw: A literature review.
Kuroshima S; Sasaki M; Sawase T
J Oral Biosci; 2019 Jun; 61(2):99-104. PubMed ID: 31109863
[TBL] [Abstract][Full Text] [Related]
26. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
[TBL] [Abstract][Full Text] [Related]
27. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.
Di Fede O; Panzarella V; Mauceri R; Fusco V; Bedogni A; Lo Muzio L; Sipmo Onj Board ; Campisi G
Biomed Res Int; 2018; 2018():2684924. PubMed ID: 30306086
[TBL] [Abstract][Full Text] [Related]
28. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
29. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.
Holtmann H; Lommen J; Kübler NR; Sproll C; Rana M; Karschuck P; Depprich R
J Int Med Res; 2018 Oct; 46(10):4277-4296. PubMed ID: 30091399
[TBL] [Abstract][Full Text] [Related]
31. Treatment of BRONJ with ozone/oxygen therapy and debridement with piezoelectric surgery.
Goker F; Donati G; Grecchi F; Sparaco A; Ghezzi M; Rania V; Rossi CA; Del Fabbro M
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9094-9103. PubMed ID: 32964999
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate-associated osteonecrosis of the jaw.
Ferreira Jr LH; Mendonça Jr KD; Chaves de Souza J; Soares Dos Reis DC; do Carmo Faleiros Veloso Guedes C; de Souza Castro Filice L; Bruzadelli Macedo S; Soares Rocha F
Minerva Dent Oral Sci; 2021 Feb; 70(1):49-57. PubMed ID: 32960522
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate-related osteonecrosis of the jaw: Current clinical significance and treatment strategy review.
Kim J; Lee DH; Dziak R; Ciancio S
Am J Dent; 2020 Jun; 33(3):115-128. PubMed ID: 32470236
[TBL] [Abstract][Full Text] [Related]
34. Review and update on drugs related to the development of osteonecrosis of the jaw.
Eguia A; Bagán-Debón L; Cardona F
Med Oral Patol Oral Cir Bucal; 2020 Jan; 25(1):e71-e83. PubMed ID: 31880288
[TBL] [Abstract][Full Text] [Related]
35. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Kishimoto H; Noguchi K; Takaoka K
Jpn Dent Sci Rev; 2019 Nov; 55(1):95-102. PubMed ID: 31193410
[TBL] [Abstract][Full Text] [Related]
36. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
37. Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis.
Devlin H; Greenwall-Cohen J; Benton J; Goodwin TL; Littlewood A; Horner K
Br Dent J; 2018 Jan; 224(1):26-31. PubMed ID: 29192692
[TBL] [Abstract][Full Text] [Related]
38. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ).
Cano-Durán JA; Peña-Cardelles JF; Ortega-Concepción D; Paredes-Rodríguez VM; García-Riart M; López-Quiles J
J Clin Exp Dent; 2017 Aug; 9(8):e1051-e1059. PubMed ID: 28936298
[TBL] [Abstract][Full Text] [Related]
39. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.
Jung J; Yoo HY; Kim GT; Lee JW; Lee YA; Kim DY; Kwon YD
J Bone Miner Res; 2017 Dec; 32(12):2445-2452. PubMed ID: 28815779
[TBL] [Abstract][Full Text] [Related]
40. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
